The major factor driving the global enteric disease testing market is the emergence of new strains of viruses and bacteria. The satisfactory improvement in testing technologies aiding in the detection and characterization of these new pathogens has also played an important role in the enteric disease testing market.
The lack of safe drinking water, sanitation and hygiene-related infrastructure in major parts of the Asia-Pacific is a major cause for high prevalence of pathogen-based infections in and around these regions. Growing awareness regarding health, introduction of rapid diagnostics tests, and the increasing financial stability of population are aiding the enteric disease testing market in these regions.
What are Enteric Diseases?
Pathogens such as bacteria, viruses and parasites cause gastrointestinal infections when they enter the body and colonize the gastrointestinal tract. Pathogens, including cryptosporidium, vibrio, c. difficile, salmonella, amebiasis, rotavirus, enterotoxigenic Escherichia coli, Shigella, and rotavirus, are traditionally known to be the principal causative agents of enteric diseases. However, many new pathogens, including genital mycoplasma, norovirus, West Nile virus, rotavirus, and respiratory syncytial virus, have emerged in the past few years.
The incubation of these pathogens in human bodies results in a variety of diarrheal diseases and infections in children as well as adults. From being asymptotic to showing mild to severe symptoms resulting in serious chronic conditions, hospitalization, or death, these infections need to be diagnosed in early stages to reduce complications.
Global Enteric Disease Testing Market - Emerging Trends
The global enteric disease testing market is segmented on the basis of the varieties of enteric diseases and their diagnostic methods. Earlier the diagnosis of enteric diseases majorly relied upon traditional testing methodologies, including passive surveillance systems such as testing the culture results of stool specimen and identifying the causative pathogen in culture medium. However, the trend is now swiftly shifting towards new and quicker diagnostic methods capable of overcoming limitations of culture tests. Major drawbacks of culture tests include labor intensive nature, high costs, and the requirement of skilled personnel and sophisticated lab-infrastructure of the process.
The entry of new tests in the market - such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) - have made diagnosis easy and faster. Rate of adoption of these methods is especially high in developed regions such as North America and Europe. The high sensitivity and specificity of these tests, combined with other benefits such as easy and rapid diagnosis are the major reasons behind their rising acceptance.
Regionally-Active Market Players
Currently, North America represents the leading regional player of the enteric disease testing market owing to high healthcare awareness and high product costs. Countries in the Asia-Pacific and Africa - housing more than half of the world’s population and counted amongst the world’s most resource-limited regions - represent the most profitable regions for the enteric disease testing market.
The lack of proper healthcare infrastructure in these regions has lead to the rising popularity of inexpensive, quick, efficient and self-diagnostic methods enabled by rapid dipstick test kits.
The global enteric disease testing market was worth US$ 3,082.6 million in 2012. According to market analysts, this would acquire a net worth of US$ 3,643.4 million by 2019 by growing at a CAGR of 2.4% in the next five years.
Rising prevalence of infections from traditional pathogens are the discovery and characterization of new varieties demand for quick and efficient diagnostics methodologies. To suffice the demand, vendors have introduced new diagnostics methods such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). To stay abreast of competitors, vendors need to devise efficient and quick diagnosis methods for new emerging pathogens.